Dilaudid Tablet and Night Sweats

Dilaudid side effects can include night sweats, nocturnal hydrosis, and hot flash like symptoms. This page helps to understand the morphine and hydromorphone side effects that cause sweating and flushing.  This drug has many warnings associated with it  regardless of purchasing discount online or generic. This information is always subject to change please consult you doctor before taking this medication. 

DESCRIPTION

Dilaudid (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic.

The chemical name of this drug (hydromorphone hydrochloride) is 4,5(alpha)-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride.

WARNINGS

Impaired Respiration:   Respiratory depression is the chief hazard of this drug ORAL LIQUID and 8 mg TABLETS. Respiratory depression occurs most frequently in overdose situations, in the elderly, in the debilitated, and in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may dangerously decrease pulmonary ventilation.

Dilaudid ORAL LIQUID and 8 mg TABLETS should be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale, patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or in patients with preexisting respiratory depression. In such patients even usual therapeutic doses of opioid analgesics may decrease respiratory drive while simultaneously increasing airway resistance to the point of apnea.

Drug Dependence:   this drug is a Schedule II narcotic. Dilaudid ORAL LIQUID and 8 mg TABLETS can produce drug dependence of the morphine type and therefore have the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of this drug, which should be prescribed and administered with the degree of caution appropriate to the use of morphine. Abrupt discontinuance in the administration of Dilaudid ORAL LIQUID and 8 mg TABLETS in patients who are physically dependent on opioids is likely to result in a withdrawal syndrome (see DRUG ABUSE AND DEPENDENCE ).

Neonatal Withdrawal Syndrome:   Infants born to mothers physically dependent on this drug will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms. (see DRUG ABUSE AND DEPENDENCE ).

Head Injury and Increased Intracranial Pressure:   The respiratory depressant effects of Dilaudid ORAL LIQUID and 8 mg TABLETS with carbon dioxide retention and secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or preexisting increase in intracranial pressure. Opioid analgesics including Dilaudid ORAL LIQUID and 8 mg TABLETS (hydromorphone hydrochloride) may produce effects which can obscure the clinical course and neurologic signs of further increase in intracranial pressure in patients with head injuries.

Hypotensive Effect:   Opioid analgesics, including Dilaudid ORAL LIQUID and 8 mg TABLETS, may cause severe hypotension in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume, or a concurrent administration of drugs such as phenothiazines or general anesthetics (see PRECAUTIONS - Drug Interactions ). Therefore, Dilaudid ORAL LIQUID and 8 mg TABLETS should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Sulfites:   Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS

Special Risk Patients:   In general, opioids should be given with caution and the initial dose should be reduced in the elderly or debilitated and those with severe impairment of hepatic, pulmonary or renal functions; myxedema or hypothyroidism; adrenocortical insufficiency (e.g., Addison's Disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; gall bladder disease; acute alcoholism; delirium tremens; kyphoscoliosis or following gastrointestinal surgery.

The administration of opioid analgesics including Dilaudid ORAL LIQUID and 8 mg TABLETS may obscure the diagnoses or clinical course in patients with acute abdominal conditions and may aggravate preexisting convulsions in patients with convulsive disorders.

Reports of mild to severe seizures and myoclonus have been reported in severely compromised patients, administered high doses of parenteral hydromorphone, for cancer and severe pain. Opioid administration at very high doses is associated with seizures and myoclonus in a variety of diseases where pain control is the primary focus.

Use in Ambulatory Patients:   Dilaudid ORAL LIQUID and 8 mg TABLETS may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g. driving, operating machinery). Patients should be cautioned accordingly. this drug may produce orthostatic hypotension in ambulatory patients. The addition of other CNS depressants to Dilaudid therapy may produce additive depressant effects, and this drug should not be taken with alcohol.

Use in Biliary Surgery:   Opioid analgesics, including Dilaudid ORAL LIQUID and 8 mg TABLETS, should also be used with caution in patients about to undergo surgery of the biliary tract since it may cause spasm of the sphincter of Oddi.

Use in Drug and Alcohol Dependent Patients:   this drug should be used with caution in patients with alcoholism and other drug dependencies due to the increased frequency of opioid tolerance, dependence, and the risk of addiction observed in these patient populations. Abuse of this drug in combination with other CNS depressant drugs can result in serious risk to the patient.

ADVERSE REACTIONS

The adverse effects of Dilaudid ORAL LIQUID and 8 mg TABLETS are similar to those of other opioid agonist analgesics, and represent established pharmacological effects of the drug class. The major hazards include respiratory depression and apnea. To a lesser degree, circulatory depression, respiratory arrest, shock and cardiac arrest have occurred.

The most frequently observed adverse effects are light-headedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain. Syncopal reactions and related symptoms in ambulatory patients may be alleviated if the patient lies down.

Less Frequently Observed with Opioid Analgesics:

General and CNS:   Weakness, headache, agitation, tremor, uncoordinated muscle movements, alterations of mood (nervousness, apprehension, depression, floating feelings, dreams), muscle rigidity, paresthesia, muscle tremor, blurred vision, nystagmus, diplopia and miosis, transient hallucinations and disorientation, visual disturbances, insomnia and increased intracranial pressure may occur.

Cardiovascular:   Chills, tachycardia, bradycardia, palpitation, faintness, syncope, hypotension and hypertension have been reported.

Respiratory:   Bronchospasm and laryngospasm have been known to occur.

Gastrointestinal:   Constipation, biliary tract spasm, ileus, anorexia, diarrhea, cramps and taste alteration have been reported.

Genitourinary:   Urinary retention or hesitancy, and antidiuretic effects have been reported.

Dermatologic:   Urticaria, other skin rashes, and diaphoresis.